StonvexLoading…
StonvexStonvexStonvexCore line items from THC's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-07-20 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $5.48B | $5.37B | $21.31B | $15.78B | $10.49B |
Operating Income | Not available | $1.30B | $3.51B | $2.65B | $1.77B |
Net Income | Not available | $906.00M | $2.37B | $1.72B | $1.14B |
EPS (Diluted) | $4.23 | $8.01 | $15.49 | $11.28 | $7.43 |
Total Assets | Not available | $31.20B | $29.68B | $29.42B | $28.70B |
Total Liabilities | Not available | $22.35B | $20.70B | $20.72B | $20.40B |
Cash & Equivalents | Not available | $2.97B | $2.88B | $2.98B | $2.63B |
Free Cash Flow OCF − CapEx | Not available | $1.46B | $2.53B | $2.16B | $1.39B |
Shares Outstanding | Not available | 87.60M | 90.83M | 91.81M | 93.41M |